This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
BERKELEY, Calif., Feb. 21, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that management is scheduled to present at three upcoming investor conferences. The details are as follows:
RBC Capital Markets Global Healthcare Conference on Tuesday, February 26, 2013 at 11:30 a.m. ET at The New York Palace Hotel
Cowen and Company 33 rd Annual Health Care Conference on Wednesday, March 6, 2013 at 8:40 a.m. ET at The Boston Marriott Copley Place
25 th Annual ROTH Conference on Monday, March 18, 2013 at 2:00 p.m. PT at The Ritz-Carlton, Laguna Niguel
Live audio webcasts of the presentations can be accessed through the Investors and Media section of XOMA's website at
http://investors.xoma.com/events.cfm . Archived versions of the webcast will be available via replay for 30 days following the presentation.
About XOMA Corporation
XOMA combines a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research, with its recently launched commercial operations. XOMA focuses its antibody research and development on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with Les Laboratoires Servier (Servier) through a global Phase 3 program in non-infectious uveitis and ongoing proof-of-concept studies in other IL-1-mediated diseases. XOMA's scientific research also produced the XMet program, which consists of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major effect on the treatment of diabetes. In order to retain significant value from its scientific discoveries, XOMA initiated commercial operations in January 2012 through the licensing of U.S. commercial rights to Servier's ACEON
® (perindopril erbumine) and a patent-protected portfolio of product candidates.
The XOMA Corporation logo is available at
More detailed information can be found at
CONTACT: Company and Investor Contacts:
The Oratorium Group, LLC